Nintedanib Mesothelioma, Searching For Targets For The Systemic Therapy Of Mesothelioma Annals Of Oncology

A new study published in the journal clinical cancer research has revealed that targeted cancer drug nintedanib is active in malignant pleural mesothelioma mpm cell models.

Printable old truck coloring pages. Malignant pleural mesothelioma mpm is an aggressive thoracic tumor type with limited treatment options and poor prognosis. Listing a study does not mean it has been evaluated by the us. Nintedanib is a type of targeted drug called a cancer growth blocker.

Standard of care treatment for unresectable mesothelioma has been relatively ineffective for many years with a one year survival rate hovering around 50 percent. In this trial some people have nintedanib. Nintedanib strongly inhibits malignant pleural mesothelioma tumor growth in human xenograft models and reduces the colony forming capacity and migratory activity of malignant pleural.

Diagnose an estimated 2500 to 3000 combined cases of mesothelioma each year. Nintedanib is active in malignant pleural mesothelioma cell models and inhibits angiogenesis and tumor growth in vivo. Nintedanib clinical trial shows promise for pleural mesothelioma mesothelioma is a rare incurable and difficult to treat cancer.

Doctors have used nintedanib in combination with chemotherapy to treat certain lung cancers but this recent designation as a promising innovative medicine pim expands its use significantly. The angiokinase inhibitor nintedanib has shown promising activity in the lume meso phase ii mpm trial and thus is currently being evaluated in the confirmatory lume meso phase iii trial. The main aims of the trial are to.

Nintedanib effective in other cancers. It stops signals that cancer cells use to divide and grow. See if nintedanib delays or stops the mesothelioma coming back after chemotherapy.

Nintedanib is marketed under the brand name ofev. Malignant pleural mesothelioma mpm is an aggressive thoracic tumor type with limited treatment options and poor prognosis. The regulatory industry in the united kingdom granted early access designation earlier this year to nintedanib for use with pleural mesothelioma.

The drug which is currently used to treat idiopathic pulmonary fibrosis scarring of the lungs with an unknown cause and for a type of non small cell lung cancer called adenocarcinoma also inhibited angiogenesis and. And some have a dummy drug placebo. Nintedanib shows promise as an addition to the standard chemotherapy regimen for pleural mesothelioma.

The cancer affects the mesothelium which is a protective membrane surrounding the pleura peritoneum and pericardium. The drug is already approved for treating pulmonary fibrosis and it is being tested in clinical trials for mesothelioma.